• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Fulvestrant ('Faslodex'): current and future role in breast cancer management.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Howell, Anthony
    Affiliation
    Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uk
    Issue Date
    2006-03
    
    Metadata
    Show full item record
    Abstract
    Fulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors. Results from two Phase III trials showed that fulvestrant is at least as effective as the third-generation selective aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer following progression on antiestrogen therapy, indicating the potential for second-line fulvestrant in this setting. In clinical practice, fulvestrant is well tolerated, with good rates of clinical benefit observed as first-line therapy and following progression on prior endocrine agents. Other endocrine agents have been shown to have good clinical activity when resistance to fulvestrant has developed, showing that fulvestrant lacks cross-resistance with other treatments. Ongoing trials are investigating the efficacy of fulvestrant after failure on aromatase inhibitors and evaluating its use in combination with therapies that target growth factor receptor signaling pathways.
    Citation
    Fulvestrant ('Faslodex'): current and future role in breast cancer management. 2006, 57 (3):265-73 Crit. Rev. Oncol. Hematol.
    Journal
    Critical Reviews in Oncology/Hematology
    URI
    http://hdl.handle.net/10541/72645
    DOI
    10.1016/j.critrevonc.2005.08.001
    PubMed ID
    16473018
    Type
    Article
    Language
    en
    ISSN
    1040-8428
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.critrevonc.2005.08.001
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The future of fulvestrant ("Faslodex").
    • Authors: Howell A
    • Issue date: 2005
    • Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    • Authors: Gradishar W
    • Issue date: 2005 Jun
    • Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    • Authors: Oakman C, Moretti E, Santarpia L, Di Leo A
    • Issue date: 2011 Feb
    • Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    • Authors: Vergote I, Robertson JF
    • Issue date: 2004 Mar
    • Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    • Authors: Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R
    • Issue date: 2007 Nov
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.